Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) is a consumer-centric digital health platform that offers access to virtual medical consultations, prescription services, and personalized treatments across areas including sexual health, skincare, mental health, and weight management. The company combines provider networks, electronic health records, and integrated pharmacy fulfillment to support a subscription-based model for delivering medications and wellness products, alongside educational resources and digital care services through its mobile apps.

As per US Dailies Report published on ‘HIMS’ on Apr 16, 2026, Kalkine provided an ‘Speculative Buy’ stance on the stock at USD 24.29 based on technical analysis and the stock price has now moved up by ~ 18.65% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

Despite strong near-term momentum driven by regulatory optimism around peptides and expanding testosterone therapy opportunities, Hims & Hers faces rising uncertainty as key growth drivers remain contingent on FDA approvals, clinical evidence requirements, and advisory committee outcomes that may not materialize as expected. The transition away from compounded GLP-1 treatments could create a near-term revenue gap, while new initiatives such as peptides and testosterone care are still in early stages with limited immediate monetization visibility.

Share Price Chart  

Conclusion

Given the sharp rally driven by regulatory optimism and event-led catalysts, appears to have moved ahead of confirmed earnings contribution and clarity on execution, a "Sell" is recommendation on Hims & Hers Health, Inc. (NYSE: HIMS) has been given at the closing market price of USD 28.82 as on 17 April 2026.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 17 April 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.